Nanotechnology is already available and has been for years. You encounter it in sunscreen, computer chips, cancer treatments, and stain-resistant clothing. The global nanotechnology market is valued at roughly $105 billion in 2025 and is projected to reach $221 billion by 2031. What most people picture when they ask this question, though, are the more dramatic applications: targeted cancer-killing particles, batteries that last for days, or water filters that make any source drinkable. Some of those are here now, some are arriving within the next few years, and others still face significant hurdles.
Nanotechnology You Already Use
If you’ve applied mineral sunscreen, you’ve rubbed nanoparticles of zinc oxide or titanium dioxide onto your skin. If you own a smartphone or laptop built in the last decade, its processor was manufactured at nanoscale dimensions. Stain-resistant fabrics, antimicrobial wound dressings, and scratch-resistant coatings on eyeglasses all rely on engineered nanomaterials. These products don’t announce themselves as “nanotechnology” on the label, which is partly why many people assume the field is still theoretical.
The U.S. National Nanotechnology Initiative credits the field with advances across aerospace, agriculture, clean energy, water purification, consumer electronics, faster microchips, and even the mRNA vaccines used during the COVID-19 pandemic. Lipid nanoparticles, the tiny fat bubbles that delivered mRNA into your cells, were one of the most widespread deployments of nanotechnology in history.
Commercially available products already include thermal management systems built from aligned carbon nanotubes, used in NASA satellites, data centers, and electric vehicles. Research funded by the USDA has produced cotton fibers embedded with silver nanoparticles for antimicrobial protection, flame retardancy, and water resistance. These aren’t prototypes sitting in a lab; they’re shipping.
Medicine: Approved Treatments and What’s in Trials
Nanoparticle-based drugs have been on the market for years. The chemotherapy drug Doxil, a liposomal formulation, was one of the earliest. More recently, Vyxeos received FDA approval in 2017 for acute myeloid leukemia. It uses a nanoparticle to deliver two chemotherapy drugs at a precise 5:1 ratio that would be impossible to maintain with a standard injection. In 2018, the FDA approved Onpattro, the first nanoparticle designed to silence a disease-causing gene through RNA interference, used to treat a rare condition where misfolded proteins damage nerves and organs.
The pipeline beyond those approvals is active. Multiple Phase I clinical trials are testing nanoparticles that carry cancer drugs directly to tumors by attaching antibodies that recognize specific markers on cancer cells. These include targeted liposomes aimed at HER2-positive breast cancer, EGFR-positive triple-negative breast cancer, and high-grade brain tumors. Another trial is testing ultrasmall silica nanoparticles, called Cornell Dots, as imaging agents that could light up melanoma and brain tumors during surgery. Phase I means these treatments are being evaluated for safety in small groups of patients, so they are likely several years from widespread availability if they succeed.
The pattern in nanomedicine is that each new approval takes a long time. Formulating a drug inside a nanoparticle, proving it reaches the right tissue, and demonstrating it works better than existing options adds years to the development cycle. Expect a steady stream of new approvals through the late 2020s and into the 2030s rather than a single breakthrough moment.
Computer Chips: The Smallest Structures in Mass Production
Semiconductor manufacturing is arguably where nanotechnology is most advanced. The transistors in current high-end processors are built at the 3-nanometer node, meaning their smallest features are just a few dozen atoms wide. TSMC, the world’s leading chipmaker, is ramping up production of its 2-nanometer process, with high-volume customer products expected to ship through 2026. Intel originally targeted early 2025 for its comparable 18A node, with initial laptop and desktop chips launching that year.
Beyond 2 nanometers, TSMC’s roadmap includes 1.6-nanometer and 1.4-nanometer technologies that will define the cutting edge for the next three to five years. Japan’s Rapidus foundry aims to start its own 2-nanometer production in 2027. These chips will power everything from AI data centers to the phone in your pocket, and each generation delivers meaningful improvements in speed and energy efficiency. This is the one area of nanotechnology where commercial timelines are measured in months, not decades.
Batteries and Energy Storage
Silicon nanowire anodes have been one of the most promising nanotechnology applications for batteries because silicon can store roughly ten times more energy per gram than the graphite used in conventional lithium-ion cells. Amprius, working with partners including BASF and Nissan, began developing silicon nanowire anodes for vehicle batteries over a decade ago. The company now produces high-energy-density cells used in aerospace and defense applications, though widespread use in consumer electric vehicles has been slower to arrive.
The core challenge is durability. Silicon expands dramatically when it absorbs lithium ions during charging, which can crack the electrode and degrade the battery over time. Nanoscale engineering, structuring the silicon as tiny wires or porous particles, helps accommodate that swelling, but achieving thousands of charge cycles at a competitive price remains an active engineering problem. Expect silicon-heavy anodes to appear in more consumer devices and eventually vehicles over the next few years as manufacturing scales up, but a full replacement of graphite anodes is still working its way through production lines.
Food Packaging and Agriculture
Smart packaging that uses nanosensors to detect food spoilage is technically functional but not yet common in grocery stores. The concept works: nanosized zinc oxide particles or other luminescent materials can sense gases produced when food begins to break down, changing color on a sensor strip to indicate whether the contents are still fresh. Electronic tongue sensors embedded in packaging can detect lactic acid, acetic acid, amines, and alcohols, all byproducts of spoilage.
Research groups are also developing “release on command” packaging, where a nano-based switch releases preservatives automatically when food is approaching spoilage. Meanwhile, the USDA is working on cellulose nanomaterial coatings for fruit that extend freshness, and nanocellulose-coated paper packaging designed to replace PFAS (the persistent “forever chemicals” currently used in food wrappers). These applications are in the pilot and scale-up phase for 2025, with commercial deployment likely within a few years for the simpler versions like freshness indicators and nanocellulose coatings.
Why Some Applications Take So Long
Regulatory review is a major factor. The U.S. EPA regulates nanoscale materials under the Toxic Substances Control Act and has reviewed over 160 new chemical notices for nanomaterials since 2005, including various forms of carbon nanotubes. The agency often permits only limited manufacturing through consent orders that restrict how the material can be used, require personal protective equipment during production, limit environmental releases, and mandate additional health and safety testing. Each new nanomaterial essentially needs to prove it won’t pose unreasonable risks before it can be manufactured at scale.
The FDA applies a similar case-by-case approach to nanomedicine. A nanoparticle drug isn’t just evaluated on whether the drug works; regulators also need to understand how the nanoparticle itself behaves in the body, where it accumulates, how it breaks down, and whether it causes unexpected immune reactions. This is why a nanoparticle cancer therapy can show promising results in early trials and still be five to ten years from pharmacy shelves.
Cost is the other bottleneck. Manufacturing nanomaterials with the consistency required for medical or food-contact use is expensive. A carbon nanotube thermal pad for a NASA satellite can justify a high price. A nanosensor built into a $4 package of chicken breasts cannot, at least not until production volumes bring the cost down dramatically.
A Realistic Timeline
Nanotechnology isn’t a single invention with a launch date. It’s a manufacturing capability that’s been rolling out in waves. Here’s a rough picture of where things stand:
- Available now: Nanoparticle sunscreens, mRNA vaccine delivery, FDA-approved nanomedicines, sub-3nm computer chips, antimicrobial nano-coated textiles, carbon nanotube thermal products.
- 2025 to 2027: 2-nanometer and smaller processor chips in consumer devices, silicon-rich nanowire battery cells in more product categories, nanocellulose food packaging replacing PFAS-based wrappers, expanded nano-based water purification systems.
- Late 2020s to early 2030s: Targeted nanoparticle cancer therapies currently in clinical trials, smart food packaging with built-in spoilage sensors at retail scale, nano-enhanced agricultural coatings in commercial farming.
The market’s projected growth from $105 billion in 2025 to $221 billion by 2031 reflects this acceleration. The technology isn’t arriving all at once. It’s already here in dozens of forms, and the next generation of applications is filling in steadily rather than waiting for a single breakthrough moment.